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Abstract 
There is considerable evidence that many disease are associated with endothelial dysfunction and 
reduced nitric oxide production such as hypertension, obesity, dyslipidemias, diabetes, heart failure, 
atherosclerosis. Notably these conditions are also characterized by alteration in the adrenergic tone. 
Whether these two mechanisms are just epiphenomenal each other or there is a functional link, it is 
still to be established. A starting ground to establish this issue is that vascular endothelium plays an 
important role in the function of cardiovascular system and that adrenergic receptors on endothelial 
cells contribute to the regulation of vasomotor tone. The aim of this excerpt is to review current 
knowledge on the physiology of endothelial adrenergic receptors to contribute to the basis for newer 
and better approaches to endothelial dysfunction in the setup of cardiovascular conditions. 
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Introduction 
The endothelium controls several vascular functions, including vasculature tone and permeability, 
thrombosis, hemostasis and angiogenesis
1-4
. It is noteworthy that all these functions can be 
regulated by the activation of receptors and often the same receptor can activate multiple 
endothelial functions. The adrenergic system is the major regulator of cardiac and vascular function 
and of endothelial vasorelaxation by means of  and  adrenergic receptors activation. The 
adrenergic receptors (ARs) are part of a large family of G protein coupled receptors (GPCR) which 
mediate the functional effects of catecholamines like epinephrine and norepinephrine. The ARs 
family includes three  (1, 2, 3), three 1 (1A, 1B, 1D) and three 2 (2A, 2B, 2C) receptor 
subtypes. These receptors actively participate to the release of nitric oxide (NO) in order to regulate 
endothelial function
5
. NO plays a crucial role in endothelium homeostasis, with important 
vasodilatory, anti-thrombotic and anti-atherogenic properties. NO mediates most of the endothelial 
functions: it has been invoked as a mechanism in vasorelaxation, endothelium permeability and 
neoangiogenesis
3
. NO in the endothelium is constitutively produced by the endothelial NO 
synthase, eNOS
6
. This latter is then further activated through calcium levels 
7
 and phosphorylation 
of various serine residues by a number of protein kinases 
8, 9
. Indeed, it has been demonstrated that 




The impaired ability of vascular endothelium to stimulate vasodilation is referred to as “Endothelial 
Dysfunction” and the major cause is the decreased bioavailability of NO in different conditions 
which can be due to various mechanisms: reduced eNOS expression, altered NO production and 
increased NO catabolism. Endothelial dysfunction plays a key role in the development of 
cardiovascular disease such as hypertension, type 2 diabetes and heart failure. The identification of 
the underlying pathogenic mechanisms will lead to the discovery of newer and more potent tools to 
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treat such diseases. On this issue, endothelial dysfunction has been associated to signal transduction 
abnormalities observed in hypertension. In particular, adrenergic vasorelaxation has been 
demonstrated to be impaired in hypertensive patients, probably due to the presence of increased 
desensitization and impaired signalling of AR. Adrenergic receptors on endothelium have been 
longely not considered functional to the regulation of the vascular tone. On the contrary, it is 
possible to identify very specific roles for such receptors in several endothelial function. This 
review will summarize the effects of adrenergic receptors on endothelial functions, focusing on 
modulation of NO synthesis and angiogenesis.  
 adrenergic receptors 
AR are GPCRs that couple to Gq protein. The Gq subunit is a primary activator of 
phospholipase C (PLC). Activation of PLC promotes the cleavage of the inositol substrate 
phosphatidyl-inositol 4,5 bisphosphate (PIP2) to yield diacylglycerol (DAG) and inositol 1,4,5-
trisphosphate (IP3). DAG and IP3 promote the activation of a protein kinase C (PKC). 1AR can 
also activate specific adenylate (adenylyl) cyclases (AC) leading to an increase in cAMP levels. The 
activation of specific PLCs and ACs requires a complex balance of signals from G-proteins, 
especially the G subunits, within specific cell contexts. DAG and cAMP are second messengers 
that affect a wide array of cell signaling pathways and responses.  
1. 1AR and Nitric oxide 
Several reports 
12, 13
 have produced evidence for the functional presence of vasorelaxant 1AR in 
the brachial and pulmonary arteries isolated from the rabbit and rat, respectively. According to these 
reports, the pharmacological stimulation of 1AR located on endothelial cells, is able to generate 
NO, whereas the stimulation of 2AR releases a relaxing prostanoid
12, 13
. Filippi demonstrated that 
nanomolar concentrations of phenylephrine, which are devoid of any contractile effect, induced a 
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slight endothelium-dependent vasorelaxation in the rat mesenteric vascular bed through the 
stimulation of 1DAR, located on endothelial cells, which act through phospholipase C stimulation, 
followed by IP1 generation, and nitric-oxide synthase activation. Conversely, the increase in 




2. 1AR and angiogenesis 
Neo-angiogenesis has long been known to be a highly ordered multistep molecular process under 
tight regulation by endothelial cells
15
 and closely associated with endothelial cell proliferation and 
migration and to the capability of these cells to modulate the levels of VEGF, the most important 
cytokine system involved in the formation of new vessels
16
. A series of biological, chemical, 
hormonal effectors can interfere with this process. Several data support the notion that α1-
adrenergic receptor should also be ranked among these agents. Indeed, it has been demonstrated that 
the 1A- and the 1B-AR subtypes but not the 1D subtype are expressed in cultured rat aorta 
endothelial cells. The activation of these 1-AR in endothelial cells provide a negative regulation of 
angiogenesis
17
. Indeed, pharmacological antagonism of 1-AR in endothelial cells from WKY rats 
by doxazosin enhanced, while stimulation of these adrenergic receptors with phenylephrine, 
inhibited endothelial mechanisms of angiogenesis such as cell proliferation and DNA synthesis, 
ERK and retinoblastoma protein (Rb) phosphorylation, cell migration and tubule formation
17
. A 
similar phenotype can be observed in vivo, since an increased 1-adrenergic receptor density in the 
ischaemic hindlimb, compared to non-ischaemic hindlimb, suggested an enhanced 1-adrenergic 
receptor tone in the ischaemic tissue. Treatment with doxazosin did not alter systemic blood 
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3. 2ARand Nitric oxide 
It has been demonstrated that 2 adrenergic agonists cause endothelium dependent relaxation, that is 
reduced or abolished by inhibitors of L-arginine/NO pathway. It depends on the activation of 2AR 
on endothelial cells which stimulates the release of NO, an action that would tend to attenuate 
vasoconstriction produced by the activation of post-junctional vascular 1AR
18-20
. The 2AR 
subtype that cause endothelium dependent relaxation belongs to the 2A/D subtype, despite the 
prominent presence of 2CAR (77% of 2C versus 23% of 2A/D)
21
. It appears that this ratio may not 
be constant, since it varies within the vascular bed. Indeed, Bockman demonstrated that in the rat 
mesenteric artery the 2AR is coupled to endothelium dependent NO-mediated relaxations and 
belongs to the 2A/D subtype appearing in its 2D version 
22
. It has been demonstrated that 
endothelium dependent relaxation to 2 adrenergic agonists is prevented by pertussis toxin 
23-28
, 
suggesting the involvement of Gi proteins in the signal transduction from the receptor to the 
activation of nitric oxide synthase 
29, 30
. Indeed, 2 adrenergic agonists cause activation of Gi 
proteins in endothelial cells and stimulate NO synthase activity 
31, 32
. Contrary to what expected, 
cAMP is not involved in the signal transduction pathway for 2A/DAR mediated NO formation 
22
. 
Indeed, the use of forskolin to oppose 2 adrenergic receptor mediated inhibition of cAMP 
formation in endothelium did not affect the relaxant response to 2AR agonists, suggesting that 
cAMP is not involved in the coupling of 2AR to NO. There are physiological modulation of 
endothelium dependent relaxation to 2 adrenergic agonists. Such relaxation is upregulated by 
chronic increase in blood flow 
33
 or exercise training 
34
. Insulin enhances NO mediated 
vasorelaxation both in animal 
25
 and human 
32
 vasculature.  
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-adrenergic receptors 
ARs signal by coupling to the stimulatory G protein, Gs, leads to the activation of adenylyl cyclase 
and accumulation of the second messenger cAMP
35, 36
. However, recent studies indicate that under 
certain conditions AR, and particularly AR, can couple to Gi as well as to Gs 
37-41
. It is now 
widely accepted that AR exist on endothelial cells 
10, 38, 40, 42
 and contribute to the regulation of 
vasomotor tone. AR are classically known to be present in the vascular smooth muscle cells 
(VSMC) where they cause vasodilation. The relative relevance of endothelial VSMC in adrenergic 
vasodilation is demonstrated by the observation that, in presence of intact endothelium, 










M). This appears to hold true through experimental models (rat or man) and 
vascular districts (see Figure 1). 
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1. 1 and 2 adrenergic receptors 
It is now recognized that βAR located in the endothelium play an important role in the relaxant 
response to ISO, since the non selective β1-and β2-adrenergic receptor antagonist propranolol 
antagonized this relaxant effect
43, 44
. However, recent studies carried out in humans, in umbilical 
veins in vitro
10
or in the forearm in vivo
45
, showed that vasorelaxation to ISO is abolished by the 
selective β2AR antagonist ICI-118551 and remains unchanged in the presence of the β1AR 
antagonist CGP-20712, indicating that, as in the vascular smooth muscle cells 
46
, the endothelial 
βAR are totally or at least predominantly of the β2 subtype 
10, 45
.  
β2AR are seven transmembrane receptors coupled through Gs proteins to a cAMP dependent 
intracellular pathway
47
. It has been demonstrated that PKA posphorylation of the third intracellular 
loop of the β2AR increases the affinity of the receptor for Gi protein
48, 49
. This switch leads to two 
consequences: first, it decreases the rate of cAMP generation, since Gi activation inhibits adenylyl 
cyclase activity. Second, it increases non cAMP dependent signaling through Gi, such as activation 
of the extracellular signal-regulated kinases ERK1/2 and PI3K
50-54
. Gi coupled receptors have been 
shown to regulate non-receptor tyrosine kinases, such as SRC, which acts as an intermediate 
between Gi and other molecules like RAS and PI3K 
53, 55
. 
2. 2AR and Nitric oxide 
For years it has been given for granted that vascular β2AR mediate adrenergic vasorelaxation 
through direct activation of vascular smooth muscle cells
56
. However, recent data challenge this 
vision, and show that β2AR-dependent vasorelaxation is mediated at least in part, by endothelium 
through nitric oxide (NO) dependent processes
10
. We have recently demonstrated that the β2AR are 
expressed on endothelial cells (EC) and their stimulation causes endothelial nitric oxide synthase 
(eNOS) activation
57
. In particular, AR couple to eNOS and induce NO dependent vasodilation 
57
. 
The mechanism of eNOS activation following β2AR stimulation is known to be AKT dependent
58
. 
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Indeed, the activity of eNOS is regulated by both a calcium/calmodulin dependent fashion
59
and 
AKT dependent eNOS phosphorylation in Ser 1177 
8, 60-63
. AKT is primarily activated in response 
to stimulation of transmembrane receptors with intrinsic tyrosine kinase activity or indirectly 
coupled to tyrosine kinases or to seven transmembrane G protein-coupled receptor
11, 61, 64
. Therefore 
AKT acts as integrator of different signal transduction pathways converging on eNOS, including 
endothelial β2AR receptor
9, 58, 62, 63, 65
. 
3. 2AR and angiogenesis 
In the endothelium ARs control other important endothelial functions like angiogenesis, that is 
tightly associated to endothelial cell migration and proliferation 
57, 65, 66
. We demonstrated that 
AR stimulation with ISO and the overexpression of AR increases endothelial cell proliferation. 
Moreover, AR stimulation induces ERK phosphorylation and the MEKK inhibitor, U0126, 
inhibits AR induced cell proliferation 
66
 suggesting that AR dependent cell proliferation is 
dependent on ERK activation. We studied post-ischaemic angiogenesis in the hindlimb (HL) of 
β2AR knock-out mice (β2AR-/-) in vivo and explored possible molecular mechanisms in vitro. 
Angiogenesis was severely impaired in β2AR-/- mice subjected to femoral artery resection, but was 
restored by gene therapy with ADβ2AR. The proangiogenic responses to a variety of stimuli were 
impaired in β2AR-/- EC in vitro
17
. Moreover, removal of β2ARs impaired the activation of NFκB, a 
transcription factor that promotes angiogenesis; ISO did not induce NFκB activation in β2AR(-/-) 
EC
17
. ADβ2AR administration restored β2AR membrane density and reinstated the NFκB response 
to ISO 
17
. These results suggest that β2ARs control angiogenesis through the tight regulation of 
nuclear transcriptional activity. 
Translational Medicine @ UniSa, - ISSN 2239-9747 2011, 1(1): 213-228 
 
222 
Università degli Studi di Salerno 
 
5. 1ARand 2AR differently regulate neo-angiogenesis 
α1- and β2-adrenergic receptors mediate opposite effects on neo-angiogenesis, comparable to their 
regulation of the vascular tone. In particular, the α1-AR is inhibitory, whereas the β2-AR is 
stimulant to neo-angiogenesis. Interestingly, in ischaemia, the α1-AR are upregulated, thus causing 
a predominance of α1-adrenergic receptor signalling over that of β2-AR, which is downregulated. 
Furthermore, in conditions such as hypertension, where the α1-AR tone is higher than that of the β2-
AR, there is also an impairment in neo-angiogenesis 
66, 67
. It is interesting to note that in the 
ischaemic hindlimb, α1-AR blockade resulted in a normalization of β2-AR density together with 
improved neo-angiogenesis. α1-AR upregulation, in particular, might be a regulatory mechanism 
aimed at preventing excessive angiogenesis. This upregulation might be triggered by ischaemia, 
through regulatory sequences within the gene promoter, which have been demonstrated for both the 




6. 3 adrenergic receptors 
In rat thoracic aorta, Trochu showed that 3AR are mainly located on endothelial cells and act in 
conjunction with 1AR and 2AR to mediate relaxation through activation of NO synthase pathway 
and subsequent increase in tissue cyclic GMP content and is reduced by endothelium removal or in 
presence of L-NMMA 
70
. This 3AR mediated aorta relaxation seems to be independent of Gi 
proteins stimulation, since the blockage of Gi protein by PTX does not modify 3AR agonists 
induced relaxation. On the contrary, selective potassium channels blockers of K (Ca), K (ATP) and 
K (v) decreased 3AR agonists induced relaxation. So it appears that this effect results from the 
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It was reported that noradrenaline-induced release of nitric oxide is enhanced in mineralcorticoid 
hypertension 
72
 indicating that 2AR may play an important role in the regulation of vascular tone 
not only in physiological but also in pathological conditions. The implications of impaired βAR 
signalling in the pathophysiology of several cardiovascular disorders has been studied in animals 
and humans. Data from these studies indicate that changes in βAR function are induced by heart 
failure 
73, 74
 and hypertension 
75, 76
. Moreover, alteration in βAR function were found also with 
physiological aging 
77, 78
, due to receptor downregulation and desensitization. Exercise restored the 
impaired signalling and AR dependent vasorelaxation
79
. We and others have observed that 
impaired βAR signalling may account for dysfunctional βAR vasorelaxation in hypertension. In this 
condition, β2AR overexpression in hypertensive rat carotids corrects impaired vasorelaxation to 
AR stimulation to levels similar to those seen in normotensive rats
57
. We proved that impaired 
endothelium dependent vasorelaxation in spontaneously hypertensive rats (SHR) can be corrected 
by increasing the signal transduction pathways leading to nitric oxide synthase activation 
80
. In 
particular, since eNOS is activated in response to phosphorylation by AKT and impaired AKT 
activity is involved in endothelial dysfunction, AKT overexpression should result in the correction 
of impaired phenotype. Indeed, insulin and ISO cause AKT membrane localization and this 
subcellular localization is impaired in SHR. AKT overexpression, through means of adenovirus 
mediated AKT gene transfer to the endothelium, increases the amount of AKT localized to the 
membrane and corrects impaired NO release and endothelium dependent vasodilation to agonists of 
both the GPCR and tyrosine kinase (TK) dependent pathways.  
Conclusions 
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In the last years great advances have been made in the study of adrenergic receptors signaling and 
function in the endothelium also thanks to the development of new technologies. Indeed, genetic 
mouse models have significantly improved our understanding of the mechanisms of action of 
specific drugs in vivo. The ability to induce transgene expression at defined times or in defined 
tissues is an important goal as well as the ability to induce or repress the expression of endogenous 
genes in a developmental or tissue specific fashion. Indeed, deletion of the genes encoding for 
adrenergic receptor subtypeshas helped to identify the specific subtypes whichmediate in vivo 
effects of specific drugs. Thus, the combination of molecular biological, genetic, and 
pharmacological techniques greatly facilitates our understanding of adrenergic receptor function in 
vivo, and in turn leads to more effective and specific therapeutic treatment in humans. ARs, for 
instance, are already target of therapeutic intervention in many diseases: AR stimulation in asthma 
and obesity or AR blocking in hypertension and coronary insufficiency. In conclusion, giving the 
importance of endothelial function in most physiological and pathological conditions, it is clear that 
the increasing knowledge of adrenergic receptors function in the endothelium is helpful for future 
progresses in clinical application.  
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Legend 
Figure 1: AR vasodilation is impaired in hypertension: A) In hypertensive patients, forearm 
vasodilation to ISO yielded an increase in forearm blood flow that was significantly lower to that 
observed in normotensive patients, at each dose of ISO. B) In hypertensive rats SHR, AR-induced 
vasorelaxation to ISO in control-treated carotids was significantly impaired compared with that 
observed in normotensive WKY(* F= 5.756,  p< 0.01, 2-way ANOVA). 
